Biomedical research network connecting iPS cells, AI evidence flows, regenerative dentistry, laboratories, and verified professional identity

Project ticker / MED

MED

A verified medical-science hub for iPS translation, regenerative dentistry, AI drug-data work, and busy researchers who need a serious room.

Scientific anchor iPS cells, regenerative medicine, AI-assisted evidence work
Bridge topic Tooth and oral-tissue regeneration as a serious translational gap
First guardrail Research ticker first; no clinical advice, token sale, or endorsement claim

Operating thesis

Japan has rare medical science depth. MED builds the connective tissue.

MED starts from a Kyoto-rooted science network: physics-trained founders, medical alumni, Dean's Club executives, iPS cell research lineage, Tokyo clinical excellence, pharmaceutical evidence pipelines, and a practical observation that dental regeneration sits between medicine, dentistry, materials science, and industry.

The first job is not to promise cures. The first job is to create a trusted room where MDs, PhDs, graduate students, corporate labs, university offices, AI agents, and selected operators can turn scattered expertise into consented problem packets, reviewable data work, and patent-ready disclosures.

MED is careful in v0.1: it does not claim formal Kyoto University, University of Tokyo, Science Tokyo, ministry, hospital, or company endorsement. Those names belong to their responsible owners until approved language exists.

Project rooms

Six rooms where busy professionals can enter without losing the thread.

Each room should produce a small public-safe packet, a private evidence trail, and a clear next reviewer.

IPS-01

iPS translation desk

Map where iPS science is close to usable translation and where AI can reduce literature, assay, manufacturing, safety, and evidence friction.

iPS cellsregenerative medicineevidence
DENT-02

Tooth regeneration bridge

Treat regenerative dentistry as a serious cross-field problem: oral biology, stem cells, biomaterials, dental schools, hospitals, and patient-safe ethics.

dentistrybiomaterialsclinical path
DRUG-03

AI drug-data room

Use AI to speed literature triage, compound and indication maps, trial evidence comparison, adverse-event signal review, and reviewer-ready summaries.

drug discoveryPMDA dataRWE
ID-04

Verified professional graph

Arrange TempleMirror-style identity for researchers, MDs, PhDs, labs, alumni executives, and reviewers with consent, attribution, and privacy boundaries.

TempleMirror IDconsentcredit
PAT-05

PAT disclosure route

Route early inventions into the PAT vertical: invention notes, prior-art maps, ownership questions, lawyer review, proof records, and filing decisions.

PATIPproof
LAB-06

Corporate and university pilot desk

Give corporate research institutes and university labs a clean way to define pilots, success metrics, confidentiality, publication policy, and review cadence.

labspilotstranslation

Operating workflow

Make it easy for the smartest people to contribute in minutes.

The workflow starts with respect for time, consent, and scientific review.

0

Invitation

One precise ask: review a topic, add a problem statement, nominate a collaborator, or flag a risk.

1

Verified identity

Optional TempleMirror-style verification separates public identity, private proof, and contribution credit.

2

Problem packet

Each idea becomes a one-page packet: clinical need, science basis, data needed, owner, and first reviewer.

3

AI triage

Agents summarize literature, datasets, patents, trials, and contradictions, then label uncertainty.

4

Human signoff

Medical and scientific reviewers approve what can be shared, what stays private, and what needs ethics review.

5

PAT route

Promising inventions move to PAT for disclosure discipline, proof records, patent counsel, and filing strategy.

First build queue

Start with problems that already have motivated reviewers.

Regenerative dentistry map

Find the scientists, dental schools, materials labs, and clinical constraints that can make tooth regeneration a real discussion instead of a wish.

iPS translation watchlist

Track active iPS topics by indication, cell type, manufacturing question, safety bottleneck, and industry partner type.

AI evidence assistant

Create one reviewer-approved workflow for literature tables, PMDA-style electronic evidence summaries, and patent/lit overlap checks.

Dean's Club invitation packet

Prepare a concise CEO-alumni ask that requests introductions, pilot framing, and corporate lab reviewers without overpromising.

Synthetic agent review

Six reviewer personas challenged the v0.1 site.

These are simulated first-pass reviewers, not real interviews. Their feedback is preserved for the next MED iteration.

Stem-cell researcher

Lead with scientific caution.

MED now says no cures, no patient recruitment, and no institutional endorsement before approval.

Dentist-scientist

Dental regeneration needs its own bridge.

The site adds a dedicated tooth and oral-tissue room instead of hiding dentistry under medicine.

Tokyo MD graduate

Clinical trust depends on governance.

Workflow now requires human signoff, ethics review routing, and separation of public/private evidence.

Corporate research lab

Define pilot entry points.

MED adds the corporate and university pilot desk with success metrics, confidentiality, and cadence.

Graduate student

Credit cannot disappear.

The professional graph and packets include consent, attribution, and publication-path checks.

Medical investor observer

Ticker language must stay disciplined.

The ticker section says MED is a project identity now, not an offer, security, or clinical claim.

Ticker and token discipline

MED can be a project ticker before it becomes anything financial.

MED should behave first like a research coordination identity: one name, one room, one clean artifact trail. If token mechanics are explored later, they should reward verified contribution, IP records, and governance work, not promise investment return or access to medical treatment.

Allowed now

Project ticker, research identity, agent-readable endpoints, review packets, PAT handoff, contribution proofs.

Not allowed now

Clinical advice, treatment claims, patient recruitment, token sale, investment-return language, unapproved university branding.